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Distal nephron function in patients receiving chronic lithium therapy.
Renal tubular function was studied in 14 patients chronically treated
with lithium for affective disorders. Patients were separated into two
groups according to the duration of lithium therapy: long-term (35 7.0
months) and short-term (4.8 0.8 months). At comparable urine
lithium concentrations, patients on long-term therapy had a lower
maximal urine osmolality (Umax) and free water reabsorption (TCH2O)
than did patients on short-term therapy. The latter group achieved a
Umax above 800 mOsm kg H20. In contrast, both groups of patients
failed to increase the urine-blood (U-B) Pco2 gradient normally during
acute sodium bicarbonate loading. This low U-B Pco2 was observed at
comparable urine bicarbonate concentrations between both groups of
patients and controls, and thus was associated with a higher urine pH in
patients. These findings indicate that the inability of these patients to
achieve a normal U-B Pco2 in a maximally alkaline urine was the result
of decreased distal hydrogen ion secretion rather than inability to raise
urine bicarbonate concentrations as a result of a concentrating defect.
Bicarbonate reabsorptive capacity was normal in our lithium-treated
subjects. Both groups of patients achieved a normal U-B Pco2 gradient
in response to sodium phosphate loading. They also were able to
achieve a minimal urine pH and a maximal acid excretion similar to
those of controls in response to a 3-day ammonium chloride loading
test. Our data demonstrate that chronic lithium therapy is associated
with a mild distal acidification defect disclosed only by the finding of a
low U-B Pco2 gradient during sodium bicarbonate loading. This pecu-
liar defect can be found in short-term lithium-treated patients in whom
the concentrating capacity is relatively well preserved.
Fonction du nephron distal chez des malades recevant un traitement
chronique par le lithium. La fonction tubulaire rCnale a été étudiée chex
14 malades traités de facon chronique par le lithium pour des désordres
affectifs. Les malades ont Cté sCparés en deux groupes en fonction de Ia
durée du traitement par le lithium: traitement a long terme (35 7 mois)
et a court terme (4,8 0,8 mois). Pour des concentrations urinaires de
lithium comparables, les malades traités a long terme avaient une
osmolalité urinaire maximale (Umax) inférieure et une reabsorption
d'eau libre (TCH2O) inférieure a celle des malades a court terme. Les
malades des deux groupes n'ont pas augmente leur gradient urine-sang(U-B) de Pco2 de facon normale au cours d'une charge aiguë en
bicarbonate de sodium. Ce gradient U-B Pco2 faible a été observe a des
concentrations de bicarbonate dans l'urine comparables entre les deux
groupes de malades et avec les contrôles, et par consequent était
associé a un pH urinaire plus élevé chez les malades que chez les
contrôles. Ces constatations indiquent que l'incapacite de ces malades a
réaliser un gradient normal dans une urine alcaline au maximum était Ia
consequence d'une diminution de Ia secretion distale d'ions hydrogCnes
plutôt que d'une incapacite a augmenter les concentrations de bicarbon-
ate urinaire consecutive a un deficit de concentration. La capacité de
reabsorption de bicarbonate était normale chez les sujets traités par le
lithium. Les deux groupes de malades ont realise un gradient U-B Pco2
normal en reporse a une charge en phosphate de sodium. Dans les deux
groupes on a obtenu un pH urinaire minimal et une excretion d'acide
maximale semblable a celle des contrôles en reponse a une charge de
chlorure d'ammonium pendant trois jours. Ces observations demon-
trent que Ic traitement chronique par Ic lithium est associé a un deficit
d'acidification distale modere mis en evidence par Ia constatation d'un
gradient faible de Pco2 entre l'urine et Ic sang au cours de Ia charge en
bicarbonate de sodium. Ce deficit particulier peut étre observe chez des
malades traités a court terme par le lithium chez lesquels Ia capacitC de
concentration est relativement bien conservee.
The proven and often unique efficacy of lithium salts in the
treatment of bipolar affective disorders is somewhat counterbal-
anced by recent reports implicating serious adverse effects on
the kidney [1—3]. These reports have shown tubular atrophy,
interstitial fibrosis, and glomerular sclerosis in renal biopsy
samples of patients on prolonged lithium therapy [I, 2]. The
specificity and significance of these pathologic changes are still
debated [4—9]. The occurrence of a concentrating defect in
lithium-treated patients has been well documented [2, 5, 10—13].
A large body of experimental evidence indicates that lithium
causes marked distal tubular dysfunction [12—23]. Furthermore,
selective histologic damage in distal convoluted tubules and
collecting ducts has been described in patients and rats receiv-
ing lithium for short periods of time [24—26].
The effect of lithium on urinary acidification has been well
studied experimentally [21—23]. In patients, lithium therapy has
been associated with an incomplete type of distal renal tubular
acidosis based on the findings of an inability to achieve a
normally low urinary pH in response to ammonium chloride
administration [27, 28]. Perez et al [29] were not able to confirm
this abnormal pattern of urinary acidification but showed that
the urinary Pco2 did not raise normally in response to chronic
sodium bicarbonate loading. These authors proposed that the
subnormal urinary Pco2 of lithium-treated patients reflected the
presence of a mild distal acidification defect [29]. Subsequently,
it was shown that the ability to raise the urinary Pco2 during
bicarbonate loading is influenced markedly by concentrating
capacity [30]. Reduced concentration ability can limit the
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achievement of high urine bicarbonate concentrations, which,
in turn, reduces urinary Pco2 [301. Because lithium often
reduces the ability to concentrate the urine, it is possible that
the low urinary Pco2 seen in patients receiving this compound
might not be the result of impaired acidification, We undertook
this study to examine renal function in patients on chronic
lithium therapy to ascertain its effect on urinary acidification
and concentrating capacity and their possible interrelationship.
Accordingly, we examined the urinary Pco2 in patients with
urinary bicarbonate concentrations comparable to that of con-
trols. The effect of duration of lithium therapy and that of
urinary lithium concentration on renal function was also exam-
ined. Our results are consistent with the presence of a distal
acidification defect in patients treated with lithium for short
periods of time and a similar defect associated with impaired
concentrating ability in patients treated with lithium for longer
periods of time.
Methods
All patients were attending the Affective Disorders Clinic of
the University of Illinois Hospital. We studied a total of 14
patients who had been receiving lithium carbonate at doses
ranging from 500 to 1500 mg daily for at least 2 months. All
patients had a bipolar manic-depressive illness and were judged
to be under good control by their psychiatrist. Each patient
gave informed written consent for studies of renal function
according to a protocol approved by the Institutional Review
Committee of the University of Illinois Hospital. No adverse
side effects occurred during these studies. These studies were
performed on an outpatient basis, and the patients were allowed
to continue their regular diets. Six patients were taking tranquil-
izers and other antidepressive drugs in addition to lithium
carbonate at the time of these studies. All patients were
euthyroid at the time of these studies.
The following protocols were followed:
(1) Baseline evaluation. At 9 A.M. two timed urine collec-
tions of approximately 60 mm each were started for measure-
ment of GFR, electrolyte excretion, and urine pH as previously
described [311. Blood determinations were made from venous
blood obtained at the midpoint of at least one of the two urine
collections. The samples were collected on ice for measurement
of blood pH and carbon dioxide tension within 15 mm of
obtaining the specimens. Blood samples for plasma creatinine
and electrolytes were simultaneously drawn. GFR was calculat-
ed by the clearance of endogenous creatinine in all patients. In a
few of them, it was also calculated from the clearance of 1251.
iothalamate as previously described [311. A member of the staff
was present during these and all other studies, which were often
conducted on several patients at the same time. This baseline
evaluation was performed in all patients during the time they
were receiving lithium. Six normal subjects underwent a similar
protocol and served as a control group.
(2) Fluid deprivation study. Patients were fasted after ap-
proximately 6 P.M. of the previous night. Plasma and urine
determinations of osmolality were made between 9 and 10 A.M.
At 10 A.M., 5 U of aqueous vasopressin (Pitressin) were given
s.c.; plasma and urine osmolality were measured from speci-
mens obtained between noon and 1 P.M. Compliance with fluid
deprivation was sought by comparing plasma sodium and
plasma osmolality measured between 9 and 10 AM. to that
observed during baseline evaluation,
(3) Acute sodium bicarbonate loading. This test served three
main purposes: (a) measurement of the U-B Pco2 gradient in a
maximally alkaline urine, (b) measurement of bicarbonate reab-
sorption, and (c) measurement of free water reabsorption
(TH2O) at different rates of osmolar clearance (Cosm).
In most patients, this test was performed immediately after
completion of the water deprivation test. This facilitated the
achievement of high urine bicarbonate concentrations (a diffi-
cult task in subjects with impaired concentrating ability) be-
cause it provided a stimulus for water reabsorption. During this
test, patients were allowed to drink small amounts of water. A
500-ml solution containing 500 mEq of sodium bicarbonate was
infused at approximately 3 mI/mm via a polyethylene catheter
inserted into one anticubital vein. Timed urine collections of
approximately 15 to 30 mm duration were obtained by sponta-
neous urine voiding in the upright position. Urine was collected
under mineral oil for measurements of urine pH and urine
carbon dioxide tension. Venous blood samples were obtained at
the midpoint of every other urine collection for determination of
blood pH and carbon dioxide tension (within 5 mm of sam-
pling), plasma osmolality, plasma creatinine, and plasma elec-
trolytes. The test was terminated after completion of at least
three urine collections with a urine pH above 7.8. This was
achieved at approximately 180 to 260 mm after the beginning of
sodium bicarbonate infusion. Four normal subjects underwent a
similar protocol and served as a control group.
Osmolar clearance (Cosm) (urine osmolality times urine flow
divided by plasma osmolality) was calculated using the periods
in which plasma determinations were made at the midpoint of
each urine collection. Free water reabsorption (TH2O) was
calculated by subtracting the urine flow from the osmolar
clearance. The effect of GFR on TCH2O was taken into account
by expressing TCH2O and Cosm as the percentage of GFR, as
follows: TH2O/GFR x 100, and C0sm/GFR X 100.
(4) Neutral sodium phosphate infusion. This test is described
separately, although it was performed on the same day of the
sodium bicarbonate test in most patients. The purpose of this
test was to measure the U-B Pco2 in a moderately alkaline urine
(that is, urine pH between 6.6 and 7.4) containing sufficient
phosphate. This required the administration of sodium bicar-
bonate in many patients. Therefore, we assessed U-B Pco2 in a
sequential manner: first during a neutral sodium phosphate
infusion at a urine pH close to 6.8 and later in a maximally
alkaline urine as described above. The rate of sodium bicarbon-
ate infusion was slowed as needed to maintain a urine pH close
to 6.8. Neutral sodium phosphate infusion was started simulta-
neously with the bicarbonate infusion; it was discontinued after
at least two urine collections with a urine phosphate concentra-
tion above 20 mmoles/liter were obtained. The dose of neutral
sodium phosphate used was 0.6 mmoles/kilo of body wt given
i.v. with 180 cc of normal saline at a rate of 1 to 1.5 mI/mm.
Timed urine collections and blood specimens were obtained as
described above. Control subjects studied during a neutral
sodium phosphate infusion have been previously reported by us
[32].
(5) Ammonium chloride loading test. Instructions to take
ammonium chloride at a dosage of 0.16 per kg of body wt daily
for 3 consecutive days were given to each patient. A nurse of
our staff contacted the patients to reinforce them to take the
ammonium chloride tablets each day. On day 4, patients
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Table 1. General data on base-line evaluation in 14 patients treated with lithiuma
Blood Blood Urine
GFR Blood
mi/mm pH
Pco2 HCO3
mm Hg
Pa PNa PK PLI Urine
pH
flow
mi/ruin
mmoles/iiter
107.1 7.38 41.8 24.6 108 142 3.98 1.08 6.48 1.64
±7.3 ±0.01 ±1.3 ±1.3 ±2.4 ±1.2 ±0.08 ±0.15 ±0.18 ±0.28
Values are the means ± SEM.
Table 2. Fluid deprivation dataa
Patients
0 Duration of
lithium therapy
months
Urine
GFR flow
mi/mm mi/mm
. Urine
lithium
mmoles/liter
Urine osmolality"
B FD
mOsmlkg H20
FD + V
Long-term therapy (N = 7) 35
±7.0
110 1.0
±0.2 ±0.2
15.4
±3.7
429
±54
581
±61
595
±71
P <0.001
Short-term therapy (N = 7) 4.8
±0.8
NS NS
120 0.8
±9.8 ±0.1
NS
16.8
±3.4
NS
557
±83
<0.02
874
±80
<0.01
876
±43
a Values are the means ± SEM.
b B is baseline; FD, 16 hours of fluid deprivation; V. vasopressin administration.
underwent a protocol identical to that described under baseline
evaluation. Urine samples were also obtained for measurement
of ammonium and titratable acidity as previously described [31—
33]. Net acid excretion was calculated by the sum of ammonium
and titratable acid excretion minus bicarbonate excretion. The 6
control subjects described on baseline evaluation also under-
went this protocol.
Results
(1) Baseline evaluation, Table 1 summarizes the biochemical
features of all patients as a group during baseline evaluation.
Notice that blood pH, blood Pco2, and blood bicarbonate were
normal. Plasma electrolytes were also in the normal range
except in one patient who had an elevated plasma sodium (151
mmoles/liter). This patient was instructed to increase his oral
fluid intake; his plasma sodium was normal thereafter.
Twelve patients had plasma lithium concentrations in the
therapeutic range (0.3 to 1.5 mmoles/liter) on baseline evalua-
tion. In the remaining two patients, plasma lithium was above
1.5 mmoles/liter (1.9 and 2.2 mmoleslliter); they had no symp-
toms of lithium toxicity except for marked polyuria and thirst.
These symptoms, however, were also present in some of the
other patients with lithium concentrations in the accepted
therapeutic range. The dose of lithium was decreased in these
two patients so that throughout the course of the following
studies, plasma lithium was below 1.5 mmoles/liter. The GFR of
the 14 patients as a group was not significantly different from
that of 6 control subjects (107.1 ± 7.3 and 96.2 ± 11 mI/mm,
respectively). Urine pH tended to be higher in lithium-treated
patients than it was in controls (6.48 ± 0.18 and 5.95 ± 0.30,
respectively); this difference, however, was not significant. The
mean age of the patients was 36 ± 5 years (range, 21 to 61
years). The mean age of controls was 34 ± 3 years (range, 23 to
54 years). Nine patients were male, and the remaining five were
female. Four control subjects were female, and two were male.
(2) Fluid deprivation test. In the 14 patients, urine flow after
fluid deprivation was 0.93 ± 0.10 mI/mm, a value significantly
lower than that observed on baseline evaluation: 1.64 ± 0.25
mi/mm, P < 0.01. Plasma sodium after 16 hours of fluid
deprivation increased significantly (144.2 ± 1.2 mmoles/liter as
compared with 140.7 ± 0.66 mmoles/liter on baseline evalua-
tion, P < 0.05). Plasma osmolality was also higher after fluid
deprivation than it was on baseline evaluation: 292.5 ± 2.3 and
286.8 ± 1.5 mOsm/kg H20, P < 0.05, respectively.
Urine osmolality after fluid deprivation was significantly
higher than it was during baseline evaluation: 723 ± 86 and 493
± 51 mOsm/kg H20, P <0.005, respectively. After vasopressin
administration, urine osmolality was 746 ± 56 mOsm/kg H20, a
value not different than that observed after 16 hours of fluid
deprivation.
We separated the patients into two groups according to the
duration of lithium therapy: Seven patients had been on lithium
for more than 1 year (range, 13 to 60 months) and seven for less
than 9 months (range, 2 to 8 months) (Table 2). This table
summarizes the data obtained after fluid deprivation in both
groups. Both after 16 hours of fluid deprivation and after
vasopressin administration, urine osmolality was significantly
lower in long-term lithium-treated patients than it was in short-
term lithium-treated patients. Of the 7 patients of the long-term
Li group, 6 did not raise urine osmolality to 700 mOsm/kg H20.
The 7th patient achieved a maximal urine osmolality of 865
mOsm/kg H20. In contrast, 6 of the 7 short-term lithium-treated
patients achieved a urine osmolality above 800 mOsm/kg H20
in response to fluid deprivation. The remaining patient failed to
achieve a urine osmolality above 700 mOsm/kg H20 after fluid
deprivation. This patient, however, was observed to have a
urine osmolality of 834 mOsm/kg H20 on baseline evaluation,
suggesting that he did not comply with fluid deprivation.
Observe from Table 2 that urine lithium concentration was
not different between the two groups. Likewise, GFR, urine
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Fig. 1. Relationship of urine-blood (U-B) Pco2 and urine bicarbonate
concentrations in controls (closed triangles), long-term lithium-treated
patients (closed circles), and short-term lithium-treated patients (open
circles).
flow, and lithium excretion were not significantly different
between the two groups.
(3) Studies during acute sodium bicarbonate infusion: (a)
Urine-blood Pco2 gradient. All 7 patients of the long-term
lithium group and 4 of the 7 short-term lithium-treated patients
were given sodium bicarbonate to achieve a maximally alkaline
urine (that is, urine pH above 7.8). Figure 1 depicts the U-B
Pco2 gradient plotted against urine bicarbonate concentrations
in these 11 patients and 4 normal subjects. It is clear from this
figure that at comparable urine bicarbonate concentrations, the
U-B Pco2 gradient was lower in patients than it was in controls.
The U-B Pco2 gradient achieved by these 11 patients was 7.1
3.7 mm Hg as compared with 41.0 5.5 mm Hg in control
subjects, P < 0.001. This difference was observed at a maximal
urine bicarbonate concentration of 138 17 mmoles/liter (pa-
tients) and 162 21 mmoles/liter (controls), NS. The maximal
urine pH achieved during sodium bicarbonate loading was
significantly higher in patients than it was in controls: 8.00
0.03 and 7.85 0.02, P < 0.05, respectively. Urine flow rates
were comparable between patients (5.5 0.9 mI/mm) and
controls (4.4 1.2 mI/mm).
In 3 of the 7 long-term lithium-treated patients, the U-B Pco2
was 4.6 5.2 mm Hg at a maximal urine bicarbonate concentra-
tion of 70.6 4.7 mmoles/liter and a urinary pH of 7.87 0.01.
Failure to increase urine bicarbonate concentration normally in
these patients was ascribed to impaired concentrating ability
because their TcH2O/GFR was markedly subnormal (—1.27
1.4% at a C0sm/GFR of 6.85 0.8%) (see below). The remain-
ing four long-term lithium-treated patients achieved a maximal
urine bicarbonate concentration similar to that of short-term
lithium-treated patients and controls. Because a concentrating
defect limits the achievement of high urine bicarbonate concen-
trations and, thus, may obscure the interpretation of the U-B
Pco2 as an index of distal hydrogen ion secretion [30, 34], only
the 4 long-term lithium-treated patients with a maximal urinary
bicarbonate concentration comparable to that of controls are
presented in Table 3. As shown in this table, the U-B Pco2
gradient was much lower in both groups of lithium-treated
patients than that of controls. Because the urinary Pco2 was
lower in patients than it was in controls and because urinary
bicarbonate concentration was similar between both groups of
patients and controls, the urine pH was higher in both groups of
patients than it was in controls. These observations were made
at comparable urine flow rates between both groups of patients
and controls. Urine lithium concentration was not significantly
different between both groups of patients.
(b) Sodium bicarbonate reabsorption. The relationship of
bicarbonate reabsorption corrected per GFR to plasma bicar-
bonate concentration is depicted in Fig. 2. At plasma bicarbon-
ate concentrations up to 25 mmoles/liter, bicarbonate reabsorp-
tion was complete in all patients. Above this level of plasma
bicarbonate concentration, its reabsorption was similar in pa-
tients and controls, being even higher in some of the patients.
Notice that a similar pattern of bicarbonate reabsorption was
observed in long- and short-term lithium-treated patients.
(c) Free water reabsorption. The increase in solute clearance
rate induced by sodium bicarbonate infusion was used to assess
free water reabsorption (TCH2O) at increasing rates of osmolar
clearance (Cosm) (Fig. 3). This figure shows that at comparable
rates of Cosm, TCH2O was lower in long-term lithium-treated
patients than in short-term lithium-treated patients. Some of the
long-term lithium-treated patients had a negative TCH2O. In
Fig. 3, the TCH2O of our patients is also compared with that of
normal subjects studied by Martinez-Maldonado et al [35]
during a 3% sodium chloride infusion. Plasma chloride and
chloride excretion did not fall in our patients during sodium
bicarbonate infusion. Therefore, sodium bicarbonate infusion
can be used to examine TCH2O at the range of Cosm observed
during 3% sodium chloride infusion [36]. Observe that three of
the four short-term lithium patients studied had a normal
TCH2O.
(4) Neutral sodium phosphate administration. A total of 9
patients (5 on long-term lithium therapy and 4 on short-term
lithium therapy) were studied. In each patient, a maximal U-B
Pco2 gradient of 30 mm Hg or above was observed when
sufficient amounts of urinary phosphate concentration were
achieved in a moderately alkaline urine (urine pH range, 6.6 to
7.4 pH units) (Fig. 4). The data of long-term (5 patients) and
short-term (4 patients) lithium groups are presented in Table 4.
Notice that blood pH, plasma phosphate, urinary phosphate
concentration, urine flow, and urine pH were comparable
between both groups of patients.
(5) Ammonium chloride loading test. After 3 consecutive
days of ammonium chloride administration, all 14 patients
studied, except 1, and the 6 control subjects, developed mild
hyperchloremic metabolic acidosis. The lowest blood pH
achieved by the 14 patients and the 6 controls was not signifi-
cantly different: 7.31 0.01 and 7.28 0.01, respectively. All
patients and controls achieved a minimum urine pH below 5.5
in response to ammonium chloride administration: 5.06 0.05
and 4.91 0.07, respectively, NS. Likewise, ammonium excre-
tion, titratable acid excretion, and net acid excretion were not
different between patients (17 2.0, 24.4 1.4, and 42.5 4.4
J.LEq/min) and controls (20.6 2.3, 25 1.5, and 45.7 3.1
Eq/min) respectively. GFR and urine flow rate were compara-
ble between patients and controls. In Table 5, the acid-base and
urinary acidification data of the patients are presented accord-
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Table 3. Urine-blood (U-B) Pc02 during sodium bicarbonate loadings
Blood Urine
.Urine
flow
.Urine
Li
U-B
Pco2Pco2 HCO3 Pco2 HCO3
Subjects pH mm Hg mmoles/liter pH mm Hg mmoles/liter mi/mm moles/mm mm Hg
Long-term therapy (N = 4) 7.47 43 31.3 8.06 51.2 148 4.3 7.0
1.1
6.2
P NS NS NS NS NS NS NS NS NS
Short-term therapy (N = 4) 7.49 52 39.9 8.02 59.7 150 5.3 4.12
1.4
10.2
P NS NS NS <0.05 <0.05 NS NS — <0.01
Controls (N = 4) 7.49 48.6 31 7.85 85.5 162 4.4 —
—
41
b NS NS NS <0.001 <0.01 NS NS — <0.05
a Values are the means SEM.
bComparison between long-term lithium patients and controls.
IL
I
Fig. 2. Bicarbonate reabsorption corrected per GFR plotted against
plasma bicarbonate in controls (closed triangles), long-term lithium
patients (closed circles) and short-term lithium patients (open circles).
ing to the duration of lithium therapy. Plasma electrolytes were
similar between both groups of patients. The minimum urinary
pH achieved by both groups of patients was similar and not
different from that of controls. Likewise, ammonium excretion,
titratable acidity, and net acid excretion were similar between
both groups of patients and that of controls. Long-term lithium-
treated patients had a blood pH higher than that of controls;
plasma bicarbonate, however, was not different.
Figure 5 summarizes the individual responses of our patients
and controls to the various maneuvers used to investigate distal
acidification. Observe that the maximal U-B Pco2 gradient (that
is, the highest value observed in each patient) during sodium
bicarbonate loading was lower than that of control subjects.
The maximal U-B Pco2 gradient observed during phosphate
loading was significantly higher than that observed during
sodium bicarbonate loading in long-term lithium patients (58.4
11.2 and 17.2 2.05 mm Hg, respectively, P < 0.01) and
short-term lithium patients (61 12 and 15.5 4.5 mm Hg,
Fig. 3. Relationship between free Water reabsorption (T'H20) and
osmolar clearance (Cog,,,). The shaded area is derived from data of
normal subjects studied by Martinez-Maldonado et al 131] during 3%
sodium chloride infusion. Long-term lithium-treated patients (closed
circles), except one, failed to achieve a normal TCH2O. Short-term
lithium-treated patients (open circles), except one, had a normal T°H20
at the range of Cosm examined.
respectively, P < 0.05). The left panel of Fig. 5 also summarizes
the maximal urine osmolality observed in each patient.
Discussion
This study shows that distal tubular function is altered in
patients chronically treated with lithium for bipolar affective
disorders. This conclusion is documented by the findings of an
inability to achieve a normal U-B Pco2 gradient in a maximally
alkaline urine in all our patients and inability to achieve a
maximal urine osmolality above 700 mOsm/kg H2O, as well as
decreased free water reabsorption in some of them.
Plasma bicarbonate, mmoles/Iiter
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Fig. 4. Relationship of the urine-blood (U-B) Pco2 gradient and urine
phosphate concentration in a moderately alkaline urine (that is, urine
pH between 6.6 and 7.4). The shaded area depicts the pattern of normal
subjects previously reported by us [32]. Long-term lithium patients
(closed circles) and short-term lithium patients (open circles) also
displayed a maximal U-B Pco2 gradient when urine phosphate concen-
tration was increased by a neutral sodium phosphate infusion. Two
values are given for each of the 9 patients studied.
In normal subjects, maximal alkalinization of the urine results
in a rise of the urinary Pco2 substantially above that of the
blood [37, 38]. The normally high U-B Pco2 gradient achieved
in a maximally alkaline urine reflects at least in part intact distal
acidification [34, 39]; thus, patients with distal renal tubular
acidosis (RTA) are unable to achieve a normal U-B Pco2
gradient in a maximally alkaline urine [34, 39]. Urinary Pco2
increases, however, not only as a result of distal hydrogen ion
secretion, but it is also dependent on urinary bicarbonate
concentration [30, 34] as depicted by the following reaction:
H + HCO3 H2C03 CO2 + H20
Impaired capacity to concentrate the urine in itself limits the
achievement of high urine bicarbonate concentrations and
thereby will shift the equilibrium of the above reaction to the
left [30, 34]. Our failure to increase urinary bicarbonate concen-
tration above 70 mmoles/liter in three patients with markedly
depressed free water reabsorption illustrates this point. Thus,
urinary Pco2 will not rise normally in patients with a concen-
trating defect, even if distal hydrogen ion secretion is normal,
inasmuch as sufficiently high urine bicarbonate concentrations
are not achieved. It follows that unless comparable urine
bicarbonate concentrations are achieved between patients and
controls, a low U-B Pco2 gradient observed during sodium
bicarbonate loading cannot be accepted as a marker of de-
creased distal acidification. This essential criteria was not met
in the only previous study in which the U-B Pco2 gradient was
examined and found to be subnormal in lithium-treated patients
[29]. In the present study, urine bicarbonate concentrations
were comparable between patients and controls (Table 3).
Because urinary Pco2 failed to increase normally in lithium-
treated patients, urinary pH was higher in patients than it was in
controls. We, therefore, conclude that the low urinary Pco2
observed in lithium-treated patients was, at least in part, the
result of decreased distal hydrogen ion secretion.
Other alternative explanations for the finding of failure of
urinary Pco2 to rise normally above that of the blood during
Sodium Neutral
bicarbonate phosphate
Fig. 5. Summary of concentrating capacity (left panel) and acidification
studies (middle and right panels) in long-term lithium patients (closed
symbols), short-term lithium patients (open circles) and controls
(closed triangles). Observe that all patients studied had a low U-B Pco2
during sodium bicarbonate loading but not during neutral phosphate
loading. Closed triangles represent three control subjects previously
reported during phosphate infusion [32]. The minimal urine pH
achieved after ammonium chloride administration was also normal in
long-term and short-term patients. Maximal urine osmolality was
clearly abnormal in all but one long-term lithium treated patient. The
asterisk identifies a short-term lithium patient in whom urine osmolality
was not measured after the fluid deprivation protocol.
sodium bicarbonate loading should be considered. It is widely
accepted that the normal rise in urinary Pco2 during alkaliniza-
tion of the urine requires delayed dehydration of carbonic acid;
this delay in carbonic acid dehydration allows the development
of a high Pco2 when the tubular urine reaches the papilla where
the surface-volume relationship is unfavorable for carbon diox-
ide diffusion [30, 34, 37]. One could speculate that lithium itself
or lithium-induced distal cell damage triggers a catalytic reac-
tion which enhances carbonic acid dehydration and thereby
prevents the normal rise in urinary Pco2. Although we cannot
exclude this possibility, the fact that lithium inhibits acidifica-
tion in the turtle bladder and causes distal RTA in animals
suggests that the low U-B Pco2 observed in our patients reflects
diminished acidification. Another possibility is that lithium
could interfere with medullary trapping of carbon dioxide. It
has been suggested that medullary trapping of carbon dioxide
can contribute to the rise of the Pco2 of the final urine during
sodium bicarbonate loading [40]. We cannot totally exclude an
interference of lithium with the medullary trapping of carbon
dioxide. But the normally high urinary Pco2 observed in our
patients during phosphate loading (see below) suggests that
medullary trapping of carbon dioxide was not impaired by
lithium. That the subnormal U-B Pco2 of our patients resulted
from decreased distal acidification rather than impaired concen-
trating ability is also supported by the fact that three patients on
short-term lithium therapy who had normal TCH2O (Fig. 3) also
exhibited a low U-B Pco2 gradient. Hence, even patients with a
well-preserved concentrating capacity are unable to achieve a
normal U-B Pco2 gradient; this strongly suggests the presence
of decreased distal hydrogen ion secretion.
Proximal bicarbonate reabsorption was normal in our lithium-
treated patients as inferred from the pattern of bicarbonate
reabsorption observed during sodium bicarbonate loading (Fig.
2). Distal acidification assessed by the U-B Pco2 gradient
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Table 4. Maximal U-B Pco2 during phosphate infusions
Patients
Blood
pH
Plasma Urine
phosphate phosphate
mmoleslliter mmoleslliter
Urine
flow
mi/mm
Urine
pH
U-B
Pco2
mm Hg
Long-term therapy (N = 5) 7.41 2.29 47 2.32 7.10 58.4
p NS NS NS NS NS NS
Short-term therapy (N = 4) 7.36 2.25 73 2.36 7.07 61
Values are the means SEM.
Table 5. Chronic ammonium chloride loading dataa
Patients
Blood
pH
Blood
Pco2 PHCO Pc1 mmoles/ Urine
mm Hg mmoles/Iiter liter pH
Urine
NH4 TA
p.Eq/min
Net
acid
Urine
flow
mI/mm
Long-term therapy (N = 7) 7.33
NS
42 21.6 113 5.10
NS NS <0.05 NS
20
NS
24
NS
44
NS
1.74
<0.025
Short-term therapy (N = 7) 7.297
NS
39 20.3 107 5.02
NS NS NS NS
14.2
NS
27
NS
41.4
NS
0.70
0.025
Controls (N = 6) 7.28
<0.005
45 21.1 108 4.91
NS NS NS NS
20.6
NS
25
NS
45.7
NS
1.19
NS
Values are the means SEM. NH4 is ammonium excretion; TA is titratable acid excretion.
achieved during neutral phosphate infusion was also normal in
all patients studied (Fig. 4). Further, administration of ammoni-
urn chloride for 3 consecutive days resulted in normal lowering
of urine pH (Fig. 5). These findings are of interest, in that they
underscore the sensitivity of the U-B Pco2 gradient in a
maximally alkaline urine as a marker of decreased distal acidifi-
cation. Because none of our patients spontaneously developed
metabolic acidosis, one could classify them as having an
incomplete form of distal RTA discerned not by failure to lower
urine pH normally but rather by the finding of a low U-B Pco2
gradient in a maximally alkaline urine.
Our findings should be contrasted with those of Perez, Oster,
and Vaamonde [271 and Miller et al [28]. These authors demon-
strated that some lithium-treated patients were unable to lower
urine pH below 5.3 in response to the short ammonium chloride
loading test described by Wrong and Davis [41]. This apparent
discrepancy with our results may be related to the fact that our
patients received ammonium chloride for 3 days and thereby
had a more sustained stimulus for distal acidification. Alterna-
tively, it is possible that some lithium-treated patients lose the
ability to lower urine pH maximally, whereas others may retain
it as exemplified by all the patients in our study. It must be
emphasized that the distal acidification defect associated with
lithium therapy is so mild that it does not compromise the renal
capacity to excrete the dietary acid load or testing doses of
ammonium chloride. Further, our patients on long-term lithium
therapy did not appear to have a more severe impairment of
urinary acidification than that of our short-term treated pa-
tients.
We know of only one patient in whom lithium toxicity was
possibly associated with metabolic acidosis and the inability to
lower urine pH normally [9]. In animals, toxic plasma lithium
levels (that is, 3 mmoleslliter) are associated consistently with
hyperchloremic metabolic acidosis and an alkaline urine [21,
22]. The acidification pattern uncovered in our lithium-treated
subjects is similar to that of lithium-induced distal RTA experi-
mentally in that phosphate infusion but not sodium bicarbonate
infusion results in a normal U-B Pco2 gradient [2 1—23, 42]. This
normal response to phosphate infusion differs from that of
patients with distal RTA secondary to a defect for hydrogen ion
secretion [32, 431 and indicates that lithium interferes with distal
acidification by a "nonsecretory" mechanism. Lithium could
reduce the normally observed electronegativity in the distal
nephron by virtue of its inhibitory effect on sodium transport [9,
19, 20]. This, in turn, could decrease distal hydrogen ion
secretion in a manner similar to that observed when lithium is
added to the mucosal side of acidifying membranes [44].
Our study also shows that prolonged duration of lithium
therapy is associated with decreased concentrating capacity as
previously reported [2—5, 10—13]. Other studies suggested that
the decline in concentrating capacity correlated with tubulo-
interstitial damage [2] and with a decreasing GFR [5]. It should
be noted that lithium concentrations, such as those found in the
urine of our patients during fluid deprivation (that is, more than
10 mmoles/liter), could theoretically account for impaired distal
H2O reabsorption. This is inferred from the studies of Singer
and Franko [45] demonstrating impaired ADH-induced water
transport using 10 m lithium concentration at the luminal site
of membranes analogous to the human collecting duct. But
because differences in lithium concentration or absolute excre-
tion were not found between our patients on short- and long-
term therapy, it is possible that the decreased concentrating
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capacity of the latter group was, at least in part, related to
structural changes in the distal nephron induced by prolonged
lithium treatment as previously suggested by other authors [2].
Our short-term lithium-treated patients achieved a Umax above
800 mOsm/kg H20. Although this clearly indicates fairly well-
preserved concentrating capacity, it is possible that prior to
lithium therapy their Umax might have been higher. Hence, we
cannot exclude a mild depression in concentrating capacity in
short-term lithium-treated patients.
Summary. Chronic lithium therapy is associated with a mild
distal acidification defect disclosed only by a low U-B Pco2 in a
maximally alkaline urine (Fig. 5). This peculiar distal acidifica-
tion defect can be seen in patients treated with lithium for a few
months who are able to concentrate the urine to normal or near
normal levels. Patients with more prolonged lithium therapy
have impaired concentrating capacity as well as a mild distal
acidification defect.
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